A May 4 article in The New Yorker on the quest to achieve true color representations in electronic displays highlighted quantum dot technology and innovations by Berkeley Lab startup Nanosys.
Second Genome, a startup based on Berkeley Lab technology, earned $42.6M in Series B round funding from the venture capital arms of Pfizer and Roche along with other investors. The company is testing a drug to treat inflammation and pain associated with ulcerative colitis, developing other therapeutics based on its microbiome research, and sequencing microbial genomes for pharmaceutical and biotech companies with its proprietary platform. Second Genome employs 26 people.
Dow AgroSciences will partner with Berkeley Lab startup TeselaGen Biotechnology to build a platform to speed discovery in new crop protection and seed products. TeselaGen offers a platform to generate cost-optimized DNA construction protocols anticipated to cut the time to identify new lead molecules for Dow’s sustainable agriculture solutions from years to months.